Tag: PA

Poster-Symptom Management

Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence

Background: Fatigue is a common symptom in patients with Multiple Sclerosis (MS). Payor databases represent an important source of real...

Read More

Poster-Quality of Life and Outcomes

Telehealth Utilization and Clinical Outcomes in Four MS Centers during the COVID Pandemic: Real-World Evidence from the MS-Cqi Improvement Research Collaborative.

Background: MS-CQI is the first multi-center improvement research collaborative for MS care. MS-CQI was a three-year study (2018-2020) to...

Read More

Poster-Quality of Life and Outcomes

Health and Wellness Needs Reported to Influence Quality of Life in People with Relapsing-Remitting Multiple Sclerosis, a Qualitative Investigation

Background: Multiple sclerosis (MS) is a chronic progressive neurological disease diagnosed commonly between 20-50 years of age, with over...

Read More

Poster-Programs

Impact of a Virtual Wellness Program on Quality-of-Life Measures for Patients Living with MS during the COVID-19 Pandemic

Background: Patients with MS are vulnerable to the effects of lack of physical activity caused by stay-at-home orders with the COVID-19...

Read More

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases

Background: Little is known about the stability of the gut microbiota in multiple sclerosis (MS) over time. Objectives: To determine if the...

Read More

Poster-Disease-modifying Therapy

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More

Poster-Disease-modifying Therapy

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More

Poster-Disease-modifying Therapy

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More

Poster-Disease-modifying Therapy

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More

Poster-Disease-modifying Therapy

Comparison of Therapy Selection Drivers within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment

Background: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with...

Read More